Guobang Pharma Ltd. (SHA:605507)

Market Cap	12.56B +19.5%
Revenue (ttm)	6.09B +1.7%
Net Income	766.47M -3.9%
EPS	1.39 -2.2%
Shares Out	558.82M
PE Ratio	16.18
Forward PE	n/a
Dividend	0.60 (2.67%)
Ex-Dividend Date	Jun 13, 2025

Volume	2,374,400
Average Volume	3,377,035
Open	22.50
Previous Close	22.48
Day's Range	21.59 - 22.53
52-Week Range	19.33 - 29.98
Beta	0.29
RSI	31.39
Earnings Date	Jul 30, 2026

About Guobang Pharma

Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives. It sells its products approximately in 117 countries and regions worldwide. The company was founded in 1996 and is based in Xinchang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 4,251
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 605507

Financial Performance

In 2025, Guobang Pharma's revenue was 6.01 billion, an increase of 2.05% compared to the previous year's 5.89 billion. Earnings were 820.82 million, an increase of 5.02%.